Bellevue Group AG boosted its position in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 41.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 129,827 shares of the medical research company's stock after buying an additional 37,744 shares during the period. Bellevue Group AG owned approximately 0.07% of IQVIA worth $30,765,000 at the end of the most recent quarter.
A number of other institutional investors have also bought and sold shares of IQV. Cetera Investment Advisers boosted its holdings in shares of IQVIA by 681.2% during the 1st quarter. Cetera Investment Advisers now owns 69,330 shares of the medical research company's stock worth $17,533,000 after buying an additional 60,455 shares in the last quarter. Cetera Advisors LLC boosted its stake in IQVIA by 28.3% during the first quarter. Cetera Advisors LLC now owns 4,464 shares of the medical research company's stock worth $1,129,000 after acquiring an additional 985 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in IQVIA by 8.3% in the first quarter. EverSource Wealth Advisors LLC now owns 1,280 shares of the medical research company's stock worth $297,000 after purchasing an additional 98 shares during the period. GAMMA Investing LLC increased its stake in IQVIA by 175.2% in the second quarter. GAMMA Investing LLC now owns 809 shares of the medical research company's stock valued at $171,000 after purchasing an additional 515 shares in the last quarter. Finally, Massmutual Trust Co. FSB ADV raised its holdings in shares of IQVIA by 39.2% during the second quarter. Massmutual Trust Co. FSB ADV now owns 994 shares of the medical research company's stock valued at $210,000 after purchasing an additional 280 shares during the period. Institutional investors own 89.62% of the company's stock.
IQV has been the subject of several research reports. Barclays reduced their target price on IQVIA from $260.00 to $255.00 and set an "overweight" rating for the company in a research note on Friday, November 1st. TD Cowen reduced their price objective on IQVIA from $270.00 to $255.00 and set a "buy" rating for the company in a research note on Friday, November 1st. BTIG Research lowered their target price on IQVIA from $290.00 to $260.00 and set a "buy" rating on the stock in a research report on Friday, November 1st. Truist Financial reduced their price target on shares of IQVIA from $286.00 to $265.00 and set a "buy" rating for the company in a research report on Monday, November 4th. Finally, Leerink Partners restated an "outperform" rating and set a $248.00 price objective (down previously from $260.00) on shares of IQVIA in a report on Tuesday, November 19th. Five equities research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $256.50.
Read Our Latest Stock Analysis on IQVIA
Shares of IQVIA stock opened at $200.84 on Friday. The business's fifty day simple moving average is $218.67 and its 200 day simple moving average is $226.17. The company has a current ratio of 0.81, a quick ratio of 0.81 and a debt-to-equity ratio of 1.76. IQVIA Holdings Inc. has a 12 month low of $187.62 and a 12 month high of $261.73. The firm has a market capitalization of $36.45 billion, a P/E ratio of 26.36, a price-to-earnings-growth ratio of 2.07 and a beta of 1.51.
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.